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Abstract: 
Purpose: Genetic ancestry influences evolutionary pathways of cancers. However, 
whether ancestry influences cancer-induced field defects is unknown. The goal of this 
study was to utilize ancestry-mapped true normal breast tissues as controls to identify 
cancer-induced field defects in normal tissue adjacent to breast tumors (NATs) in women 
of African American (AA) and European (EA) ancestry. 
Experimental Methods: A tissue microarray (TMA) comprising breast tissues of ancestry-
mapped 100 age-matched healthy women from the Komen Tissue Bank (KTB) at Indiana 
University and tumor-NAT pairs from 100 women (300 samples total) was analyzed for 
the levels of ZEB1, an oncogenic transcription factor that is central to cell fate, mature 
luminal cell enriched estrogen receptor alpha (ER), GATA3, FOXA1 and for immune 
cell composition.  
Results: ZEB1+ cells, which were localized surrounding the ductal structures of the 
normal breast, were enriched in the KTB-normal of AA compared to KTB-normal of EA 
women. By contrast, in EA women, both NATs and tumors compared to KTB-normal 
contained higher levels of ZEB1+ cells. FOXA1 levels were lower in NATs compared to 
KTB-normal in AA but not in EA women.  We also noted variations in the levels of 
GATA3, CD8+ T cells, PD1+ immune cells, and PDL1+ cell but not CD68+ 
macrophages in NATs of AA and EA women. ER levels did not change in any of our 
analyses, pointing to the specificity of ancestry-dependent variations.  
Conclusions: Genetic ancestry-mapped tissues from healthy individuals are required for 
proper assessment and development of cancer-induced field defects as early cancer 
detection markers.   
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Translational Relevance: Breast cancer diagnosis prior to lymph node metastasis can 
appreciably improve clinical outcomes. While radiologic techniques have improved early 
diagnosis, molecular markers that can complement radiologic techniques are needed to 
improve specificity. This study aimed to investigate how both genetic ancestry and 
appropriate control tissues influence detection of cancer-induced changes in the breast. 
We show that alterations in ZEB1+ cells in tissues surrounding tumors are observed 
predominantly in women of European ancestry, whereas FOXA1+ cells were altered in 
normal tissues adjacent to tumors of women of African American Ancestry. Immune cell 
activation in tumors as well as surrounding tissue showed genetic ancestry-dependent 
variations as evident from differences in PD1+ and PDL1+ cells in the normal tissue 
adjacent to tumors of women of African American and European Ancestry. Thus, 
biomarker discovery needs to consider not only sample size and statistical methods but 
also genetic ancestry and true normal control tissues. 
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Statement of Significance: We demonstrate that genetic ancestry mapped tissues from 
healthy individuals are required as controls to identify cancer-induced field defects in 
tumor-adjacent normal tissues as well as defects in tumors. This finding is significant in 





 Recent data demonstrating a correlation between lymph node positivity at the 
time of detection, and the probability of disease recurrence even decades post detection, 
only solidifies the principle that detection of breast cancer prior to lymph node metastasis 
can appreciably improve clinical outcomes (1). Although the last decade witnessed 
significant improvements in imaging technologies including 3D-mammography, false 
negatives remain a significant concern (2).  One way to overcome these false negatives is 
to complement radiologic techniques with molecular assays that measure “transcriptomic 
and epigenetic field effect” of tumors on adjacent “normal” (NATs) tissues.  
Teschendorff et al demonstrated tumor-induced epigenetic field defects in NATs 
specifically targeting transcription factor binding sites specifying chromatin architecture 
and stem cell differentiation pathways (3).  These include Wnt and FGF signaling 
networks. Unfortunately, the Tumor Genome Atlas (TCGA) of breast cancer utilized 
reduction mammoplasty or NATs as their controls in transcriptome analyses (4).  These 
are often substituted for “normal” controls in comparative analyses with breast cancers. 
This limitation was highlighted in another study, which compared TCGA “normal” breast 
transcriptome with the transcriptome of epithelial cells from the breast of healthy women.  
Significant differences were noted between these two sources of normal tissues (5).  
Reduction mammoplasty samples are also histologically abnormal compared to breast 
tissues from healthy women (6).  
While molecular markers of cancers, particularly gene expression signatures, are 
traditionally developed by comparing gene expression between available “normal” and 
cancer tissues, the possibility of genetic ancestry of samples having an impact on gene 
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expression under normal and abnormal conditions is rarely taken into consideration. The 
effects of genetic ancestry on tumor evolution and gene expression are just beginning to 
be recognized (7). This observation is highly relevant in the context of known differences 
in cancer incidence and/or outcome based on genetic ancestry. For example, women of 
African American ancestry (AA) suffer higher mortality from the aggressive breast 
cancer subtype, triple negative breast cancer (TNBC), than women of European Ancestry 
(EA) (8). By contrast, breast cancer in Hispanic and Native American women is less 
prevalent and these women have better outcomes (9,10).  Whether the worse outcome in 
AA women is due to an increased incidence of TNBC or unique biological factors that 
promote aggressive biology is an important but unresolved challenge in cancer disparities 
research.   Dietze et al.(8) recently highlighted that key molecular pathways, including 
Aurora A-PLK, EZH2, and Wnt-stem cell signaling networks, are significantly 
upregulated in TNBCs of AA women compared to TNBCs of EA women.   The review 
(8) further emphasized that it remains unknown whether genomic aberrations unique to 
TNBCs in AA women result in activation of these signaling pathways in tumors or 
whether the basal activity of these pathways in normal AA women’s breasts is inherently 
different compared to EA women’s breasts.   It remains possible that normal breast 
biology varies based on genetic ancestry.  Evidence for this possibility comes from a 
recent discovery of breast cancer protective alleles in Latinas (11).  Single nucleotide 
polymorphisms (SNPs) in the protective allele are located on gene regulatory regions 
affecting the expression of genes linked to differentiation. Our own studies have 
discovered enrichment of a unique population of cells in the normal breast of AA women 
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(12).  Furthermore, a breast cancer susceptibility locus in AA women, potentially altering 
the expression levels of microRNA miR-3065, has recently been described (13).   
Here, we took advantage of genetic ancestry mapped true normal breast tissues to 
identify differences between true normal and NATs. These differences can potentially be 
developed into the earliest markers of breast cancer initiation. A tissue microarray (TMA) 
comprising breast tissues from clinically normal breasts, NATs and tumors were analyzed 
for markers that are expressed in cells with stem or mature luminal cell properties. We 
also examined the TMA for CD8+ T cells, CD68+ macrophages, PD1+ immune cells, 
and PDL1+ epithelial cells to determine whether immune cell composition of tumors and 
NATs in AA women differ from those of EA women. 
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Materials and Methods:  
Generation of tissue microarray (TMA). Breast core biopsies from healthy women 
donated to the Komen Tissue Bank (KTB) at Indiana University and surgical material left 
over after pathologic assessment as part of a treatment protocol were obtained after 
informed written consent from the subjects. All experiments were carried out in 
accordance with the approved guidelines of the Indiana University Institutional Review 
Board. International Ethical Guidelines for Biomedical Research Involving Human 
Subjects were followed. We created a tissue microarray comprising healthy breast tissue 
from the KTB (KTB-normal), matched normal adjacent to tumor (NAT) and tumor tissue 
of ~50 each of African American and Caucasian women (total ~300 samples).  KTB-
normal tissues were age- and race-matched to NATs/tumors.  BMI of AA women who 
donated tissues to KTB was 32.3±9, whereas it was 28.3±8.5 in case of Caucasian 
women.  Each sample was spotted in duplicate in cases of NATs and tumors.   
Immunohistochemistry and statistical analyses: TMA was analyzed for ZEB1, 
MSRB3, estrogen receptor alpha (ER), FOXA1, and GATA3 expression.  All 
immunohistochemistry (IHC) was done in a CLIA-certified histopathology lab and 
evaluated by three pathologists in a blinded manner. Quantitative measurements were 
done using the automated Aperio Imaging system and analysis was done using an FDA 
approved algorithm.  Positivity and H-scores were scored and statistically analyzed as 
described previously (14,15).   With respect to PD1 and PDL1, a tumor proportion score 
(TPS) was created. The PD1 and PDL1 followed the prescribed FDA reading of TPS 
<1% positive staining, negative; TPS 2 to 49% tumor cells positive, and TPS greater than 
50% tumor cells positive (16,17). Data were analyzed in three different ways: 1) 
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Expression differences between AA and EA KTB-normal; 2) Expression differences 
between KTB-normal and NATs; and 3) Expression differences between NATs and 
tumors. The statistical software SAS version 9.4 was used to complete the statistical 
analyses with p < 0.05 considered significant. Non-parametric Wilcoxon rank-sum tests 
were used for unpaired analyses, as positivity and H scores were not normally distributed, 
whereas non-parametric Wilcoxon signed-rank tests were used for paired analyses. The 
following antibodies were used: CD8 (Dako IR623), CD68 KP1 (Dako IR609), ER 
clone:EP1 (Dako IR 084), FOXA1 (Santa Cruz sc-6553), GATA3 (Santa Cruz sc-268) 
MSRB3 (HPA014432, rabbit polyclonal, Sigma), PD1 (Cell Marque 315M-98), PDL1 





ZEB1+ cells are enriched in the normal breasts of AA women compared to EA 
women: In the mouse mammary gland, PROCR+/EpCAM- cells are purported to 
function as multi-potent stem cells (18).  In our previous study focused on evaluating 
ethnicity-dependent differences in the normal breast, we observed specific enrichment of 
PROCR+/EpCAM- cells in cultured normal breast epithelial cells from biopsies of 
healthy AA women compared to EA women (12).  These cells are enriched for the 
expression of stemness-related transcription factor ZEB1 and have enhanced Wnt 
pathway activity compared to PROCR±/EpCAM+ cells (12).  ZEB1 has recently been 
demonstrated to limit onco-suppressive p53-driven DNA damage response in stem cells 
and thus increase the stem cells’ intrinsic susceptibility to malignant transformation (19).  
ZEB1+ cells co-express the methionine sulfoxidase reductase (MSRB3), which protects 
against DNA damage (19). These observations raise the possibility that PROCR+/ZEB1+ 
cells are naturally present at a higher levels in the normal breasts of AA women and that 
failure to consider natural variation in gene expression pattern, influenced at least 
partially by genetic ancestry, could have an impact on identifying cancer-induced field 
effect on the adjacent normal breast. Measuring PROCR itself in the breast tissue is 
complicated because there are four haplotypes of PROCR due to SNPs and only one 
among them is a cell surface protein (20).  Since ZEB1 expression is enriched in 
PROCR+/EpCAM- cells, we used ZEB1 as a surrogate marker for PROCR+/EpCAM- 
cells in un-manipulated breast tissues.  
Representative IHC staining patterns of ZEB1 in KTB-normal, NATs, and tumors 
from AA and EA women are shown in Figure 1A and statistical analyses are presented in 
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Figure 1B-D and in Table 1.  Descriptive statistics of ethnicity, age, menstrual status, 
pregnancy and breastfeeding history, hormone replacement therapy and family history of 
breast cancer for the KTB-normal cohort is shown in Table S1. Highly discriminative 41-
ancestry marker profiles of KTB-normal showed >75% African ancestry markers in 
samples from African American women and >80% European ancestry markers in 
Caucasian women (Figure S1A) (21). Characteristics of breast cancer in the tumor cohort 
are shown in Table S2. ZEB1 expressing cells are localized outside the ductal structures 
of the normal breast and in the stromal part of the tumors (enlarged version on right side 
of Figure 1A).  KTB-normal breast tissue of AA women contained significantly higher 
levels of ZEB1-positive cells compared to KTB-normal breast of EA women (Figure 1B).  
NATs of AA women showed a modest increase in ZEB1+ cells compared to those of 
KTB-normal (Figure 1C and D).  The scenario was completely different in EA women; 
both NATs and tumors contained significantly higher levels of ZEB1+ cells compared to 
KTB-normal tissue (Figure 1C and D).  NAT to tumor differences were noted only in EA 
women where an increase in ZEB1+ cells was noted predominantly in ER+ tumors 
(Table S3).  Thus, ZEB1+ cells are intrinsically higher in the normal breasts of AA 
women, whereas remarkably elevated ZEB1+ cells in the breasts of EA women were 
observed only in the context of breast cancer.  Increases in ZEB1+ cells in KTB-normal 
tissue of AA women compared to EA women is less likely related to BMI differences. 
This was demonstrated by subdividing women above and below BMI of 30, irrespective 
of genetic ancestry; ZEB1 H-score but not positivity showed a marginal relationship 
(p=0.04) to BMI above and below 30 (Table S4).  
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MSRB3 has recently been shown to be one of the downstream transcriptional 
targets of ZEB1 and it cooperates with ZEB1 during transformation of stem-like cells 
(19). To correlate ZEB1 expression with its activity, we measured the levels of MSRB3 
using the same antibody used in the above study. We could measure positivity but not H-
score because of low-level expression. The expression pattern was similar to that of 
ZEB1, as cells surrounding the ducts showed expression (Figure S1B). However, KTB- 
normal tissues of AA and EA women expressed similar levels of MSRB3 (Table 1 and 
Figure S1C), which could be due to regulation by other transcription factors or to the low 
expression levels, making data interpretation difficult.  Furthermore, except for a modest 
change in expression in NATs compared to KTB normal tissues, no other differences 
were noted (Figure S1C and D). 
FOXA1 expression is lower in NATs of only AA women: FOXA1 serves as a pioneer 
factor that controls chromatin access of various nuclear receptors including ER and 
controls the expression of genes enriched in luminal cells compared to basal cells (22-
24).  FOXA1 along with another pioneer factor GATA3 and ER form a lineage 
restricted hormone-responsive signaling network in the normal breast (25).  While higher 
expression of FOXA1 in the primary tumor is associated with better outcome, its 
overexpression in metastatic and/or anti-estrogen resistant tumors is associated with 
rewiring of ER signaling and poor outcome (26-29).  In addition, it is suggested that 
FOXA1 gene is preferentially methylated in tumors of AA women (30).  Because of its 
relative importance in breast cancer, we assessed our TMA for FOXA1 expression.  
Representative staining pattern of FOXA1 is shown in Figure 2A and numerical values 
are presented in Table 1.  While FOXA1 levels in KTB-normal tissues of AA women 
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were modestly higher than in EA women, NATs of AA women had lower FOXA1 
compared to KTB-normal tissues (Figure 2B).  Thus, tumors through their field effect 
may decrease FOXA1 in the surrounding breast tissues of AA women.  
GATA3 levels are higher in KTB-normal of EA compared to AA women: We also 
examined expression levels of GATA3 to determine whether hormonal signaling 
networks show genetic ancestry-dependent variation. Consistent with this possibility, 
GATA3 H-score and positivity were higher in KTB-normal tissues of EA women 
compared to those of AA women (Table 1 and Figure S2B). Furthermore, GATA3 is a 
likely candidate for cancer-induced field defects in EA women as its levels were 
significantly lower in NATs of EA but not AA women compared to their KTB-normal 
counterparts (Figure S2C).  
ER+ cells remain stable: ER-positive cells in the normal breast are considered to be 
highly differentiated non-proliferative cells and control proliferation of ER-negative 
cells through paracrine mechanisms (31).  Representative ER staining pattern is shown 
in Figure 3A and statistical analyses are presented in Figure 3B-D and Table 1.  Neither 
KTB normal tissues nor NATs showed genetic ancestry-dependent differences in ER 
levels.  The results are not only relevant, but also reassure that our TMA detects only 
specific changes.   
ER status in tumors influences differences between NATs and tumors:  Although 
we observed differences in ZEB1, GATA3, and ER expression between NATs and 
tumors (Figures 1D, 2D, 3D and S2D), interpretation of these data is difficult because of 
differences in characteristics of breast cancer subtypes, particularly ER-positive and 
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ER-negative (32).  To determine whether ER-positive and ER-negative tumors have 
distinct effects on NATs, FOXA1, GATA3, and ZEB1 expression data in NATs and 
tumors were subdivided based on ER status of the tumor and reanalyzed.  ZEB1-
positivity and H-scores were higher in ER-positive but not ER-negative tumors 
compared to NATs (Table S3). Despite small sample size, these differences were noted 
only in EA women with ER+ breast cancers (Table S3). With respect to FOXA1, H-
score but not positivity was marginally higher in ER-positive tumors compared to 
NATs of EA women (Table S3). ER-negative tumors of EA but not AA women showed 
a significant decline in both positivity and H-score of FOXA1 compared to NATs (Table 
S3). ER-positive tumors but not ER-negative tumors showed further increase in 
GATA3 positivity and H-scores in EA women, which further confirms the role of 
GATA3 in hormonal regulation of breast cancer (Figure S2D and Table S3). When the 
analyses was done with paired NAT-tumors, the above noted differences between NATs 
and tumors in ZEB1, GATA3, and FOXA1 levels remained significant, although sample 
size was too small to subdivide samples based on genetic ancestry (Table S5).  
NATs of AA and EA women show differing levels of CD8, PD1 and PDL1+ cells: 
Results thus far point to pro-inflammatory state of NATs of EA women based on the 
known link between ZEB1 and inflammatory cytokines (33).  To address this further, we 
stained the above TMAs with CD8 for T cells, CD68 for macrophages, and PD1 for 
immune cells.  We also examined epithelial/tumor cells for PDL1. All staining was done 
in a CLIA-certified lab with FDA-approved antibodies. In KTB-normal TMAs, there was 
no staining with CD8 and CD68 in either the AA or EA TMAs.  Less than 1% of the 
lymphocytes and macrophages stained and these were considered negative.   The same 
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negativity was observed with PD1 and PDL1 immunostains (data not shown). Therefore, 
we analyzed staining results between NATs of AA and EA women and between NATs 
and tumors. Representative staining patterns in NATs and tumors are shown in Figure 4. 
CD8 immunostaining was localized to inflammatory cells (T lymphocytes) and 
not to tumor cells in the breast cancer cores.   No background reactivity was observed in 
any case. NATs of AA women showed statistically significantly higher CD8 positivity 
compared to EA women (Figure 5 and Table S6). The tumors in EA women had more 
CD8 immunostaining compared to corresponding NATs but such differences were not 
seen in the AA women.   
CD68 staining was localized to macrophages in the breast cancer cores (Figure 4).  
CD68 had lower positivity compared to CD8 by both visual and the Aperio positive pixel 
reads.  CD68 positivity was higher in tumors compared to their NATs (p=0.02) in EA 
women but no such differences were noted in AA women (Figure 5). 
PD1 immunostaining was localized to immune cells only and no background 
staining was observed (Figure 4).   There was no staining of tumor cells.  NATs of AA 
women contained significantly higher PD1+ cells, similar to CD8+ cells, compared to 
NATs of EA women (Figure 6 and Table S6). PD1 staining did not show any differences 
between NATs and tumors in both groups (Table S3).  
PDL1 immunostaining was seen localized in the tumor cell cytoplasm and cell 
membrane (Figure 4).  In a few EA cases, only lymphocytes were stained.  PDL1 staining 
of NATs of AA women was significantly lower than EA cases (Figure 6 and Table S6).  
Although PDL1 staining did not differ between NATs and tumors of AA women, its 
levels were marginally lower in ER+ tumors but not ER- tumors compared to NATs in 
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case of EA women (Figure 6 and Table S3).  It is interesting that PD1 and PDL1 staining 
scores in NATs of AA is the reverse of the patterns seen in EA women. In summation, 
the immune environment in NATs is different from that in KTB-normal tissue with 





Recent studies have shown cancer-induced field defects influencing gene 
expression patterns in histologically normal tissues surrounding cancer (3,34,35). These 
observations raise a concern as well as provide an opportunity for further investigation. 
The concern is the use of tumor adjacent normal as a “normal” control, whereas the 
opportunity pertains to the development of cancer-induced field defects in the adjacent 
normal as early markers of cancer. However, recent discovery of inter-individual 
differences in gene expression patterns due to SNPs in gene regulatory regions and 
genetic ancestry-dependent enrichment of SNPs with breast cancer protective or elevated 
risk characteristics necessitate the use of ancestry-matched control samples from healthy 
individuals to develop molecular features of tumor adjacent normal as cancer-initiation or 
progression markers (11,13,36,37). Ethnicity contributing to inter-individual differences 
in normal biology is just beginning to be explored, as evident from a recent study that 
demonstrated distinct gut microbiota in different ethnic groups with shared geography 
(38). Furthermore, genetic ancestry has been shown to influence mutation patterns in 
cancer (7). Resources available at the Komen Normal Tissue Bank at Indiana University, 
namely ancestry-mapped breast tissues from >5000 healthy women, should enable us to 
take these factors into consideration as we develop molecular features of NATs as cancer 
detection markers. Utilizing a small fraction of those tissues, we provide evidence for 
ancestry-dependent differences in the number of ZEB1-positive and GATA3-positive 
cells in the normal breast as well as cancer-induced field effects on ZEB1, GATA3, and 
FOXA-positive cells in the tumor-adjacent normal tissue. 
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   Recently discovered functions of ZEB1 have raised considerable interest in this 
molecule within the oncology field. The regulatory regions of this gene remain in a 
bivalent state, enabling the regulatory regions to respond readily to the tumor 
microenvironment and increase breast cancer plasticity and tumorigencity (39). Another 
study showed elevated ZEB1 expression in normal breast stem cells and it functionally 
protects stem cells from p53-mediated cell death in response to oncogene activation-
induced DNA damage and promotes tumorigenecity with limited genomic instability 
(19). It was also reported that ZEB1 is expressed in both tumor and stromal cells of the 
breast (40). ZEB1 directly increases the expression of pro-inflammatory cytokines such 
as IL-6 and IL-8, and it promotes vascular mimicry of breast cancer cells by remodeling 
extracellular matrix (33,41). We had previously demonstrated that cytokines such as 
tumor necrosis factor induce the expression of ZEB1 (42). These observations along with 
our unique observations of genetic ancestry-dependent differences in ZEB1-positive cells 
in the normal breast, elevated number of ZEB1+ cells in NATs compared to healthy 
breast tissues of women of European ancestry, and its localization outside the ductal 
structures raise several questions about the function of ZEB1+ cells in the normal and 
tumor adjacent normal breast. We have shown previously that cytokeratin-positive, 
PROCR+/EpCAM- cells of the normal breast, which are enriched in the normal breast of 
AA women compared to EA women, express 50-fold higher ZEB1 compared to 
cytokeratin-positive, PROCR-/EpCAM+ cells of the breast (12,43). Thus, we suspect that 
ZEB1+ cells in the normal breast correspond to PROCR+/EpCAM- cells and that cancer-
induced field effect leads to expansion/proliferation of such cells in the breast of EA 
women. Signaling pathways leading to proliferation of ZEB1+ cells in NATs of EA 
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women are unknown, but the Wnt pathway is the prime suspect as it is activated in cells 
surrounding cancer due to altered DNA methylation (3). In this respect, Wnt and ZEB1 
constitute a reciprocal feed-forward signaling loop where ZEB1 enhances TCF4/-
Catenin-mediated transcription and Wnt signaling converts ZEB1 from a transcription 
repressor to an activator (44).  
The reason for an intrinsically higher number of ZEB1+ cells in AA women is 
unknown. TNBCs in AA compared to EA women display elevated Wnt pathway 
activation and it could be that Wnt pathway activity is intrinsically higher in AA women 
leading to elevated ZEB1 expression (8). It has also been demonstrated that vitamin D 
through Vitamin D Receptor (VDR) represses ZEB1 expression and serum vitamin D 
levels are significantly lower in AA than EA individuals (45,46). Therefore, lower VDR 
activity and resulting increase in the activity of pro-inflammatory cytokines could be 
responsible for higher number of ZEB1+ cells in the normal breast of AA women, which 
needs further investigation. 
In contrast to stemness-associated ZEB1, FOXA1 and GATA3, which are 
expressed predominantly in differentiated luminal cells, showed opposite pattern in AA 
women. While the normal breasts of AA women had higher number of FOXA1-positve 
cells compared to EA women, a decline in FOXA1-positive cells in NATs as a 
consequence of cancer field effect is observed only in AA women. How tumors cause 
down regulation of FOXA1 in NATs is unknown but could involve inflammatory 
cytokines, as cytokine inducible transcription repressors such as TWIST1 repress FOXA1 
expression (47,48).  In this regard, we observed genetic ancestry-dependent differences in 
the levels of immune cells in NATs; NATs of AA women contained an elevated number 
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of CD8+ T cells and PD1+ immune cells compared to NATs of EA women. In addition, 
FOXA1 regulatory regions are highly susceptible for DNA methylation and 
transcriptional repression, particularly in the context of BRCA1 deficiency (49). 
Furthermore, ER-negative tumors in AA women show elevated FOXA1 DNA 
methylation compared to ER-negative tumors of EA women (30). Recent studies have 
also demonstrated racial differences in plasma levels of cytokines with CCL2, CCL11, 
IL4, and IL10 being higher in EA women, and IL1RA and IFN2 being higher in AA 
women (50).  
Differential expression of GATA3 in the normal breasts of AA and EA women is 
intriguing, as GATA3 is one of the major signaling molecules required for hormonal 
response and differentiation of normal breast epithelial cells (25). Our results suggest that 
hormonal- and differentiation-signaling networks show genetic ancestry-dependent 
differences and it is likely that ERGATA3-dependent transcriptional program is more 
active in the normal breast of EA compared to AA women. Whether such difference 
between EA and AA persist in ER-positive tumors is unknown and potentially worth 
investigating as it is relevant for response to antiestrogen therapy. 
Collectively, data presented in this study suggest the need to consider the 
following aspects for cancer biomarker discovery: 1) NATs are molecularly abnormal 
and thus not suitable as controls; 2) These abnormalities can be detected only when true 
normal breast tissues are used as controls and differences in normal gene expression 
attributable to genetic ancestry are taken into consideration; 3) ZEB1 and GATA3 show 
unique expression pattern in the normal breast influenced by the genetic ancestry and 
could potentially be developed as biomarkers of breast cancer initiation of women of 
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European Ancestry; and 4) Genetic ancestry has an influence on the immune environment 
of tumors as well as NATs.   
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Figure 1: ZEB1 expression pattern in KTB-normal, normal adjacent to tumor (NATs) 
and in breast tumors. A) Representative immunohistochemistry of KTB-normal, NATs 
and tumors of women of African American (AA) and European Ancestry (EA). Enlarged 
view of a KTB-normal is shown on right (top). B) Differences in ZEB1 expression 
(positivity and H-score) between KTB-normal of AA and EA women. C) Differences 
between KTB-normal and NATs in AA and EA women. D) Differences between NATs 
and tumors in AA and EA women. 
 
Figure 2: FOXA1 expression pattern in KTB-normal, NATs and in breast tumors. A) 
Representative immunohistochemistry of KTB-normal, NATs and tumors of AA and EA 
women. Enlarged view of a KTB-normal is shown on right (top). B) Differences in 
FOXA1 expression (positivity and H-score) between KTB-normal of AA and EA 
women. C) Differences between KTB-normal and NATs in AA and EA women. D) 
Differences between NATs and tumors in AA and EA women. 
 
Figure 3: ER expression pattern in KTB-normal, NATs and in breast tumors. A) 
Representative immunohistochemistry of KTB-normal, NATs and tumors of AA and EA 
women. Enlarged view of a KTB-normal is shown on right (top). B) Differences in ER 
expression (positivity and H-score) between KTB-normal of AA and EA women. C) 
Differences between KTB-normal and NATs in AA and EA women. D) Differences 
between NATs and tumors in AA and EA women. 
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Figure 4: Representative CD8, CD68, PD1 and PDL1 immunohistochemistry of NATs 
and Tumors of AA and EA women. 
 
Figure 5: Statistical analyses of CD8 and CD68 positivity in NATs and tumors (T) of 
AA and EA women. All statistically significant differences are indicated with p values. 
 
Figure 6: Statistical analyses of PD1 and PDL1 TPS scores in NATs and tumors (T) of 




Table 1: Differences in expression levels of ER, FOXA1, GATA3, MSRB3, and ZEB1 
in KTB-normal between women of African American and European ancestry 
 







N Median Minimum Maximum N Median Minimum Maximum 
ER 
Positivity 
38 0.009837 0.001769 0.085101  39 0.010387  0.000000 0.064659 0.8345 
ER H 
Score 
38 2.165487  0.315269  21.777591  38 2.265046  0.103586 17.165665  0.7514 
ZEB1 
Positivity 
38 0.004324  0.000316  0.025044  41 0.001224  0.000221 0.028532  <0.0001** 
ZEB H 
Score 
38 0.931903 0.045633 5.926867 41 0.157922 0.026349 3.927299 <0.0001** 
FOXA1 
Positivity 
42 0.037941 0.010844 0.147725 47 0.021856 0.007987 0.171964 0.0033** 
FOXA1 
H Score 
42 5.108708 1.414022 20.066698 47 3.126083 1.033697 23.666012 0.0031** 
GATA3 
Positivity 
27 0.009031 0.001339 0.048353 32 0.018617 0.003970 0.067257 0.0009** 
GATA3 
H Score 
27 1.656681 0.170409 10.399523 32 4.020432 0.589316 17.773060 0.0003** 
MSRB3 
Positivity 
29 0.006854 0.002061 0.035347 26 0.006474 0.002085 0.034037 0.4040 
 
 
 






